The phase 3 ROCKET HORIZON trial showed promising results for rocatinlimab, an investigational therapy for atopic dermatitis that targets inflammation. The study achieved its co-primary endpoints with significant improvement in signs and symptoms of the disease compared to a placebo. The therapy targets the OX40 receptor, a key driver of inflammation in atopic dermatitis. The results were statistically significant, with a higher percentage of patients treated with rocatinlimab achieving IGA-AD 0 or 1 and EASI 75 by week 24 compared to the placebo group. Adverse events were comparable to previous study results. Kyowa Kirin plans to release full results at a medical conference.
Source link
Rocatinlimab exhibits positive results in phase 3 study for atopic dermatitis
